Jump to content

Ro-44-3888

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 20:46, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ro-44-3888
Identifiers
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H24N4O5
Molar mass376.4 g/mol g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N1CCC(CC1)OCC(=O)O)NC(=O)C2=CC=C(C=C2)C(=N)N
  • InChI=1S/C18H24N4O5/c1-11(21-17(25)13-4-2-12(3-5-13)16(19)20)18(26)22-8-6-14(7-9-22)27-10-15(23)24/h2-5,11,14H,6-10H2,1H3,(H3,19,20)(H,21,25)(H,23,24)/t11-/m0/s1
  • Key:BHOGTSLQMNCJHA-NSHDSACASA-N

Ro 44-3888 is a non-peptidic, selective and reversible glycoprotein IIb/IIIa inhibitor. It is the active metabolite of sibrafiban. It was being investigated as a treatment for heart conditions, including myocardial infarctions. The development of Ro 44-3888 and sibrafiban was discontinued in 1999 following unfavorable Phase III efficacy data.

See also

Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ro-44-3888&oldid=713239714"